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Targeting the Palm: A Leap Forward
Toward Treatment of Keratin
Disorders
Wera Roth1, Mechthild Hatzfeld2 and Thomas M. Magin1
Any rational therapy benefits from an understanding of basic biology and the
simplicity of its strategy. Among keratinopathies, epidermolytic palmoplantar
keratoderma stands out by virtue of hotspot mutations in the KRT9 gene,
exclusively expressed in the palmoplantar epidermis. In this issue, Leslie Pedrioli
et al. report on the successful application of KRT9-specific siRNAs in cultured cells
and in a mouse model. The study beautifully illustrates the potency of a thorough
experimental approach and the challenges that remain, especially in its delivery.
Journal of Investigative Dermatology (2012) 132, 1541–1542. doi:10.1038/jid.2012.99
Efficacy, specificity, and potency of a drug
represent the lynchpins of a successful
therapy. In the case of genetic disorders,
onset of disease and the cell type of origin
mount additional hurdles to be overcome.
Keratinopathies are caused mostly by
dominant mutations in at least 23 of the
54 human keratin genes expressed as
the ‘‘keratin pairs’’ that typify epithelial
differentiation (Szeverenyi et al., 2008;
http://www.interfil.org). Therefore, sites
of expression reveal the major site(s)
of disease, despite the notion that
most keratinocytes express 4–10 different
keratin proteins. Further, there appears to
be reasonable genotype–phenotype corre-
lation, indicating that mutations severely
compromising the cytoskeleton’s integrity
cause more severe disease phenotypes
than those that do not. Although patho-
mechanisms of the keratinopathies are
more complex than originally thought
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(Coulombe and Lee, 2012), one can
reasonably argue that reducing the
expression of the mutant allele in domi-
nant keratin disorders should restore a
more functional cytoskeleton from the
intact allele, leading to greater tissue
integrity. Proof of principle stemmed
from mouse models in which the ratio of
mutant and normal keratin alleles has
been modified genetically (Cao et al.,
2001; Hesse et al., 2007).
Among keratinopathies, epidermo-
lytic palmoplantar keratoderma (EPPK)
is unique for several reasons: the expres-
sion of the culprit, KRT9, is restricted
to the upper strata of the palmo-
plantar epidermis, forming a cytoskele-
ton together with at least six additional
keratins. The majority of EPPK patients
suffer from a missense mutation in one
of the three hotspot codons, giving rise
to a focal epidermolytic keratoderma
(http://www.interfil.org). This setting
invited Leslie Pedrioli et al. (this issue,
2012) to develop an siRNA-based ther-
apy approach, testing both generic and
mutation-specific siRNAs directed against
KRT9. The team first scanned all possible
19-mer siRNAs for the repression of KRT9,
using transiently expressed luciferase
reporters to monitor specificity and
efficacy of siRNAs. Next, siRNAs that
efficiently inhibited the two prominent
KRT9 missense mutations M157V and
R163Q were identified using a similar
strategy. The best siRNAs were able to
repress a mutant KRT9 allele in the 50 pM
range, without apparently affecting the
expression of other keratins. Ultimately,
siRNAs must be delivered in situ. Unfortu-
nately, no mouse model for KRT9 is
currently available. As a first step, Leslie
Pedrioli et al. coinjected the most potent
siRNA, siR163Q-13, together with a
mutant KRT9-luciferase reporter carrying
the same mutation, into mouse foot-
pad epidermis. This delivery route had
been previously approved in a phase Ib
clinical trial for pachyonychia congenita
(Leachman et al., 2010). To test for
specificity, a wild-type KRT9-luciferase
reporter was applied together with the
above siRNA in another footpad. Despite
the limitations imposed by the nature of
the delivery, i.e., injection, the data sug-
gest that the siRNA was more specific in
repressing the mutant compared with the
normal allele.
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As one finds with any good study,
Leslie Pedrioli and colleagues’ data raise
a number of issues that in the above
setting relate to RNAi, keratin biology,
and skin physiology. The specific and
effective repression of mutant KRT9
alleles is supported by encouraging
data in model systems for the related,
dominant keratinopathies pachyony-
chia congenita, epidermolysis bullosa
simplex, and Meesmann corneal
dystrophy (Leachman et al., 2010; Liao
et al., 2011; Coulombe and Lee, 2012).
These studies imply that specifically
targeting individual keratin mutations is
feasible, although current bioinforma-
tics approaches are unable to deliver
reliable predictions. Further, siRNA
complexed into stable nucleic acid
particles appears to be stable for up to
2 weeks (Davidson and McCray, 2011).
Whether the use of repeated cycles of
siRNA that are necessary to treat chronic
diseases will avoid immunological recog-
nition through RIG and TLR receptors
expressed in keratinocytes remains to be
determined. The stability of the target
mRNA and encoded protein(s) represents
another challenge. The long half-
life of keratin intermediate filament pro-
teins and their mRNAs may indeed outlast
most siRNA formulations. Therefore,
including data from well-established
three-dimensional keratinocyte culture
models is of paramount importance
in future studies. In combination with
experiments on animal models, the
question of how efficient siRNA-mediated
repression of mutant keratins must be
in order to eliminate dominant-negative
effects remains to be answered.
In many epidermal keratinocytes, ker-
atins represent some of the most abun-
dant proteins. Current studies on treating
keratinopathies with siRNAs assume that
repressing a single keratin isotype, i.e.,
KRT9 as in the Leslie Pedrioli et al. (this
issue, 2012) paper, is of little conse-
quence for skin integrity and physiology
in view of keratin’s abundance and their
complexity of expression. This may not
be the case and is not well supported by
in vivo data. The only supporting mouse
studies are those of the functional
replacement of KRT18 by KRT 19 and
the partial replacement of KR14 by
KRT18 (Hutton et al., 1998; Magin
et al., 1998). More recent data, rather,
point to non-overlapping keratin func-
tions, spear-headed by KRT17’s role in
control of protein biosynthesis and
inflammation (Coulombe and Lee,
2012). With these and additional data
in mind, future studies should include
more comprehensive assays to evaluate
treatment success in the context of skin
physiology.
Delivery in vivo is the
major limitation in
applying siRNA
technology to skin
diseases.
In addition, the greatest hurdle for
siRNA-based treatment of skin disorders
remains delivery to the cell of origin.
Recent advances in lipid-mediated
nucleic acid delivery to the skin have
considered trans- and intracellular, as
well as transfollicular and transappenda-
geal, routes to treat a range of genetic
and non-genetic conditions (Geusens
et al., 2011). The truth is that the under-
lying mechanisms for successful deli-
very of nucleic acids (the basis of any
ex vivo therapy into live keratino-
cytes, including stem cells) are not well
known. As odd as it seems, there is no
other way than back from bedside to the
bench: are all keratinocytes equal in their
ability to take up, transport, and process
siRNAs? Which of the aforementioned
routes are actually being taken by siRNA
that is delivered to cells? How many
stem cells are targeted, and does resto-
ring their phenotype confer a selective
advantage over their neighbors? These
are some of the questions that must be
answered before the exciting strides
taken by Leslie Pedrioli et al. (this issue,
2012) find their way to the clinic.
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